Navigation Links
Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
Date:11/25/2008

es the future for our most advanced asset. Importantly, we have appreciated the positive chemistry between Cephalon and ourselves and believe we would work well together," said Dimitri Dimitriou, CEO of ImmuPharma.

About Lupuzor and Lupus

Lupuzor is a first-in-class immune modulating treatment that has shown, through a unique mechanism, to modulate a specific subset of CD4 T cells which has been shown to play a critical role in the physiopathology of Lupus. This experimental medication has the potential to halt the progression of the disease in a substantial proportion of patients. Composition of matter patents for Lupuzor have been approved in Japan and Australia and the US Patent Office recently issued a notice of allowance.

Lupus is an autoimmune disease causing various effects throughout different parts of the body. Its severity can range from very mild to extremely serious depending on which body organs are afflicted. The Lupus Foundation of America estimates that 1.5 million Americans have a form of lupus. Approximately 90 percent of those diagnosed with the disease are women. Lupus is two to three times more prevalent among people of color, including African Americans, Hispanics/Latinos, Asians, and Native Americans.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Mais
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
2. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
3. Ohio Sales Reps Information Launched Massive Government Investigation of Cephalon
4. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
5. Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA
6. Cephalon Conference Call Invitation
7. Cephalon Reports Strong First Quarter Earnings
8. Cephalon Appoints Gerald J. Pappert as General Counsel
9. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
10. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
11. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LEXINGTON, Ky (Sept. 17, 2014) -- Two independent ... PhD, of the University of Kentucky, and Charles ... published important studies exploring the role that a ... cardiovascular disease. , According to Whiteheart, previous genome-wide ... as a factor that regulates a protein called ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... CAMBRIDGE, Massachusetts, U.S.A., September 18, 2014 -- BGI ... sequencing service to Denmark-based DLF-Trifolium and the Department ... University in an effort to develop a series ... genomic selection (GS) methods. , GS is a ... contrast to the traditional QTL-based selection, uses information ...
(Date:9/18/2014)... September 18, 2014 CRDF Global ... first ever digital edition – rich with videos, ... of how CRDF Global empowers scientists and innovators ... of government, corporate, foundation and individual supporters, CRDF ... innovators in research, training and entrepreneurship. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
Breaking Medicine News(10 mins):Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3
... to detect suspicious activity in airports, stadiums and other ... researcher who invented them to find and measure potentially ... professor of Computer Science and one of the world,s ... computer imaging, has received $400,000 from the National Institutes ...
... about the importance of eye assessments for babies during June,s ... 2 When should a parent schedule a comprehensive eye ... at 6 months, the average baby has reached a number ... the first eye and vision assessment. , , According ...
... for space headache to be established as a new ... astronauts, published in the June issue of Cephalalgia ... headaches are normally caused by space motion sickness, after ... no connection. "Our research shows that space flights ...
... device will facilitate single port access laparoscopic surgery , ... privately held biomaterials-based medical device company, announced today that ... and Drug Administration to market the InnoPort(TM) to facilitate ... The InnoPort is inserted into the abdomen to perform ...
... , - Free health clinics facing crisis of increasing demand, ... hand in helping make donation possible , , - ... banks in December , , RICHMOND, Va., June 2 ... announced today it is donating $1 million to free health ...
... ... at trial, and bring Attorneys state of the art fall prevention and protection training. ... (PRWEB) June ... settlements, assist representation at trial, and bring Attorneys state of the art fall prevention ...
Cached Medicine News:Health News:UCF researcher developing computer program to detect, measure brain tumors 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 2Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 3Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 4Health News:Make Sure Your Baby is Seeing the Most Important Things in His World 5Health News:Researchers call for new space headache category following astronauts' survey 2Health News:Innovia Receives FDA Clearance For The InnoPort(TM) 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 2Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 3Health News:Dominion Helps Communities by Donating $1 Million to Health Clinics 4Health News:Fall Prevention/Protection - Slip and Fall Accredited Training for Legal Practices 2
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... MADISON, N.J., Jan. 6, 2012 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today the ... Health System to acquire S.E.D. Medical Laboratories. Under the ... assets of S.E.D. Medical Laboratories and will manage in-patient ...
... 2012 In preparation for meetings starting Monday, ... scheduled for 10:00 a.m. Thursday, January 12 at ... Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the fourth quarter 2011:       -Approximately 935-950 ...
Cached Medicine Technology:Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories 2Questcor Pharmaceuticals Reports Strong Finish to 2011 2Questcor Pharmaceuticals Reports Strong Finish to 2011 3Questcor Pharmaceuticals Reports Strong Finish to 2011 4Questcor Pharmaceuticals Reports Strong Finish to 2011 5Questcor Pharmaceuticals Reports Strong Finish to 2011 6
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: